B

BridgeBio Pharma
D

BBIO

36.830
USD
0.02
(0.05%)
مغلق
حجم التداول
106,998
الربح لكل سهم
-4
العائد الربحي
-
P/E
-15
حجم السوق
6,960,494,408
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AACG
    0.07430
    (8.54%)
    0.94430 USD
    ABBV
    ABBV
    1.200
    (0.60%)
    202.140 USD
    A
    ABCL
    -0.10500
    (-3.34%)
    3.04000 USD
    ABEV
    ABEV
    0.02500
    (1.31%)
    1.93000 USD
    A
    ALB
    -1.320
    (-1.60%)
    81.220 USD
    A
    ALLO
    -0.07500
    (-3.33%)
    2.17500 USD
    A
    ALT
    -0.19000
    (-2.87%)
    6.42000 USD
    A
    AMRN
    -0.00130
    (-0.22%)
    0.58930 USD
    A
    AMRX
    -0.03500
    (-0.44%)
    7.84500 USD
    A
    ANAB
    -0.260
    (-1.38%)
    18.570 USD
    A
    ASB
    -0.650
    (-2.59%)
    24.440 USD
    A
    AXDX
    0.08000
    (7.21%)
    1.19000 USD
    A
    AXSM
    8.550
    (6.62%)
    137.720 USD
    B
    BCRX
    -0.17000
    (-1.81%)
    9.20000 USD
    المزيد
الأخبار
المقالات

العنوان: BridgeBio Pharma

القطاع: Healthcare
الصناعة: Biotechnology
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.